Pfizer to study pneumococcal, COVID-19 vaccine combo in older adults

By The Science Advisory Board staff writers

May 24, 2021 -- Pfizer has launched a study that is investigating the coadministration of the company's pneumococcal vaccine (20vPnC) and its Pfizer-BioNTech COVID-19 vaccine in adults 65 and older.

The main purpose of the study is to assess safety when both vaccines are administered together with a six-month follow-up. The trial includes 600 adults who will have received their second dose of Pfizer's COVID-19 vaccine at least six months before the coadministration study.

Participants will be randomized into three groups:

  • Pneumococcal vaccine plus COVID-19 vaccine booster
  • Pneumococcal plus a placebo
  • COVID-19 vaccine booster and a placebo

The Pfizer-BioNTech COVID-19 vaccine is based on messenger RNA (mRNA) technology and has been shipped to 91 countries and territories around the world as part of an emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA).

The company's pneumococcal vaccine was accepted for priority review for a biologics license application by the FDA in December 2020 and marketing authorization application review by the European Medicines Agency in February 2021. The vaccine includes capsular polysaccharide conjugates for 20 serotypes that are responsible for a majority of currently circulating pneumococcal disease globally.

Copyright © 2021

Create an Account

Already have an account? Sign in Here

To access all ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for

Email Preferences

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.